Salim Yazji
Chief Tech/Sci/R&D Officer bei ONCTERNAL THERAPEUTICS, INC.
Vermögen: 57 888 $ am 31.03.2024
Profil
Salim Yazji is the founder of Elpida Therapeutics and Ajuta Therapeutics, Inc. He currently holds the position of Director at Versatope Therapeutics, Inc. and Chief Medical Officer at Oncternal Therapeutics, Inc. His former positions include Vice President-Global Therapeutics at Baxalta, Inc., Chief Medical Officer & Executive Vice President at Calimmune, Inc., and Chief Medical Officer at PMV Pharmaceuticals, Inc. Yazji holds a doctorate degree from Pavlov First Saint Petersburg State Medical University.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
14.02.2024 | 6 432 ( 0,22% ) | 57 888 $ | 31.03.2024 |
Aktive Positionen von Salim Yazji
Unternehmen | Position | Beginn |
---|---|---|
ONCTERNAL THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 17.05.2021 |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | Director/Board Member | 01.04.2019 |
Elpida Therapeutics | Founder | - |
Ehemalige bekannte Positionen von Salim Yazji
Unternehmen | Position | Ende |
---|---|---|
BAXALTA INC | Corporate Officer/Principal | - |
PMV PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
Calimmune, Inc.
Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | Chief Tech/Sci/R&D Officer | - |
Ajuta Therapeutics, Inc. | Chief Executive Officer | - |
Ausbildung von Salim Yazji
Pavlov First Saint Petersburg State Medical University | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PMV PHARMACEUTICALS, INC. | Commercial Services |
ONCTERNAL THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Baxalta, Inc.
Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Calimmune, Inc.
Calimmune, Inc. BiotechnologyHealth Technology Calimmune, Inc. operates as a clinical-stage biotechnology company. The firm offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. The company was founded by David Baltimore, Inder M. Verma, Irvin Chen and Louis Breton in 2006 and is headquartered in Tucson, AZ. | Health Technology |
Versatope Therapeutics, Inc.
Versatope Therapeutics, Inc. BiotechnologyHealth Technology Versatope Therapeutics, Inc. is an immuno-therapeutic company based in Lowell, MA. The private company harnesses a customized biotechnology platform to deliver immunity using state-of-the-art synthetic biology and bioinformatics. The company customizes exosome-like vesicles made from probiotics to display targets in a 3D context that activates potent immunity. The company's lead vaccine candidate addresses the need for improved, effective universal influenza vaccines to prevent influenza and other emerging infectious diseases, such as the current COVID-19. The company was founded in 2017 by Christopher Locher and Dave Putnam, and Christopher Locher has been the CEO since 2017. | Health Technology |
Ajuta Therapeutics, Inc. | |
Elpida Therapeutics |